A year after trial failure, AstraZeneca withdraws Imfinzi's maiden indication in bladder cancer — but execs look to the bright side
Lung cancer is the arena where AstraZeneca’s Imfinzi has made its mark, but those who have watched the PD-L1 drug since it was still …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
